Sysmex (OTCMKTS:SSMXY) Sees Large Volume Increase – Still a Buy?

Sysmex Corporation ADR (OTCMKTS:SSMXY – Get Free Report) saw strong trading volume on Tuesday. 500,977 shares changed hands during mid-day trading, an increase of 160% from the previous session’s volume of 192,975 shares. The stock last traded at $11.7863 and had previously closed at $11.72.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Sysmex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Hold rating. According to data from MarketBeat.com, Sysmex presently has an average rating of “Hold”.

Get Sysmex alerts:

Get Our Latest Analysis on SSMXY

Sysmex Stock Performance

The business’s 50-day simple moving average is $11.83 and its two-hundred day simple moving average is $9.98. The firm has a market cap of $7.14 billion, a price-to-earnings ratio of 27.95 and a beta of 1.18. The company has a quick ratio of 2.53, a current ratio of 3.40 and a debt-to-equity ratio of 0.23.

Sysmex (OTCMKTS:SSMXY – Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.02. Sysmex had a return on equity of 8.01% and a net margin of 7.62%. The company had revenue of $825.85 million for the quarter, compared to analysts’ expectations of $741.67 million. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, sell-side analysts expect that Sysmex Corporation ADR will post 0.41 earnings per share for the current fiscal year.

Sysmex Company Profile

(Get Free Report)

Sysmex Corporation is a Japan-based healthcare technology company that develops, manufactures and distributes in vitro diagnostic products and laboratory solutions. The company is best known for its automated hematology analyzers, which are used to examine blood cells, along with related reagents, software and support services.

Its product portfolio also includes systems for hemostasis, urinalysis, clinical chemistry and immunochemistry, as well as laboratory automation and information-management solutions.

See Also

• Five stocks we like better than Sysmex
• Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
• IonQ Fell 9% on a $1.3 Billion Deal—Is Wall Street Missing Something?
• JPMorgan Earnings Miss Estimates But Reveal Broad-Based Strength
• Flex’s AI Infrastructure Spin-Off Could Unlock Hidden Value

Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.